Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

In an interview with pharmaphorum, Dion Warren, head of Takeda's European oncology business, said it is hoping to broaden its cancer portfolio. Reports surfaced last year suggesting the firm had ...

The move aims to strengthen Takeda's oncology pipeline. From the effective date of the agreement, the company will be responsible for all subsequent development activities. The company will pay ...

Takeda is upping its commitment to cancer after its Shire takeover with the announcement of three new research collaborations in immuno-oncology. In the first deal, Takeda will collaborate with ...

The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.

M&T Bank Corp lowered its position in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 10.0% in the 4th ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands ...

A long-standing debate over the most effective treatment for prevalent forms of colorectal cancer — the world’s third most diagnosed cancer — was finally settled in June 2022. The much ...

Sanctuary Advisors LLC cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 57.9% ...